Journal articles on the topic 'He53'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'He53.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Kent, Matthew R., Delia Calderon, Katherine M. Silvius, Jack P. Kucinski, Collette A. LaVigne, Matthew V. Cannon, and Genevieve C. Kendall. "Abstract 3533: Zebrafish her3 knockout impacts developmental and rhabdomyosarcoma-related gene signatures." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3533. http://dx.doi.org/10.1158/1538-7445.am2023-3533.
Full textBeckford Vera, Denis, Jason Li, Le-Cun Xu, Debbie Lewis, Amanda Chin, Patrik Brodin, Mary Chen, Monideepa Roy, and Helen Kotanides. "Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e15114-e15114. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15114.
Full textKoyama, Kumiko, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Yang Qiu, Kenji Nakamaru, and Masato Murakami. "Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression." PLOS ONE 17, no. 5 (May 3, 2022): e0267027. http://dx.doi.org/10.1371/journal.pone.0267027.
Full textKomatsu, Nagiho, Saori Sato, Sumie Muramatsu, Ryuichi Nakamura, and Kumiko Koyama. "Abstract 3996: The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody-drug conjugate." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3996. http://dx.doi.org/10.1158/1538-7445.am2023-3996.
Full textO'Hare, Thomas, Jaclyn Cleveland, Valerie M. Jansen, and David Dornan. "Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers." Cancer Research 84, no. 6_Supplement (March 22, 2024): 3121. http://dx.doi.org/10.1158/1538-7445.am2024-3121.
Full textBeckford-Vera, Denis, Megan McCloskey, Jason Li, Caroline Jennings, Le-Cun Xu, Debbie Lewis, Patrik Brodin, et al. "Abstract 5040: Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors." Cancer Research 83, no. 7_Supplement (April 4, 2023): 5040. http://dx.doi.org/10.1158/1538-7445.am2023-5040.
Full textToy, Weiyi, Dipti Thakkar, Roberto Magallanes, Sharon Wu, Ming Poi, Alejandro Mas, Konrad Paszkiewicz, Piers Ingram, and Jerome Boyd-Kirkup. "Abstract 5796: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations." Cancer Research 84, no. 6_Supplement (March 22, 2024): 5796. http://dx.doi.org/10.1158/1538-7445.am2024-5796.
Full textBeckford-Vera, Denis, Jason Li, Megan McCloskey, Caroline Jennings, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen, and Helen Kotanides. "Abstract 3306: Targeting HER3 receptor positive cancers with a novel anti-HER3 antibody radioconjugate (ARC)." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3306. http://dx.doi.org/10.1158/1538-7445.am2022-3306.
Full textScartozzi, M., A. Mandolesi, R. Giampieri, A. Zaniboni, E. Galizia, L. Giustini, R. R. Silva, R. Berardi, I. Bearzi, and S. Cascinu. "The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab." Journal of Clinical Oncology 29, no. 4_suppl (February 1, 2011): 404. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.404.
Full textMartinez Lago, Nieves, Ihab Abdulkader, Dora Insua Santamaria, Patricia Viaño Nuñez, Juan Jose Carrera, Jose Ramón Antunez Lopez, Maria Elena Padin Iruegas, and Rafael López López. "Assessment and prognostic impact of a new classification using HER2 and HER3 status in resected gastric cancer in a european cohort." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 65. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.65.
Full textMukherjee, Sumit, Debbie Lewis, Jason Li, Le-Cun Xu, Amanda Chin, Mary Chen, Monideepa Roy, et al. "Abstract A149: Characterization of HER3 targeted radioligand therapy using molecular imaging." Molecular Cancer Therapeutics 22, no. 12_Supplement (December 1, 2023): A149. http://dx.doi.org/10.1158/1535-7163.targ-23-a149.
Full textXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young Jin Gi, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, and Naoto T. Ueno. "Abstract LB088: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd) in tamoxifen-resistant ER+ breast cancer cells by reprogramming cell cycle progression." Cancer Research 82, no. 12_Supplement (June 15, 2022): LB088. http://dx.doi.org/10.1158/1538-7445.am2022-lb088.
Full textBeckford-Vera, Denis, Jason Li, Caroline Jennings, Megan McCloskey, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen, and Helen Kotanides. "Abstract 609: Anti-HER3 radioimmunotherapy enhances the anti-tumor effects of CD47 blockade in solid tumors." Cancer Research 82, no. 12_Supplement (June 15, 2022): 609. http://dx.doi.org/10.1158/1538-7445.am2022-609.
Full textChang, Chi-Son, Jung In Shim, Sun-Ju Byeon, Eun Jin Lee, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, and Chel Hun Choi. "Prognostic Significance of HER3 Expression in Patients with Cervical Cancer." Cancers 14, no. 9 (April 25, 2022): 2139. http://dx.doi.org/10.3390/cancers14092139.
Full textChang, Chi-Son, Jung In Shim, Sun-Ju Byeon, Eun Jin Lee, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, and Chel Hun Choi. "Prognostic Significance of HER3 Expression in Patients with Cervical Cancer." Cancers 14, no. 9 (April 25, 2022): 2139. http://dx.doi.org/10.3390/cancers14092139.
Full textAmin, Dhara N., Natalia Sergina, Lionel Lim, Andrei Goga, and Mark M. Moasser. "HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells." Biochemical Journal 447, no. 3 (October 5, 2012): 417–25. http://dx.doi.org/10.1042/bj20120724.
Full textRajendran, Rithika, Coen Johannes Gerardus Lap, Fayez Estephan, Shanshan Liu, Ramesh Subrahmanyam, Guoqing Diao, Victor Nava, and Maneesh Rajiv Jain. "Prevalence of HER3 expression in prostate adenocarcinoma and its clinicopathological characteristics." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): 5019. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5019.
Full textYonesaka, Kimio, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, et al. "Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402)." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21175-e21175. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21175.
Full textYonesaka, Kimio, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, et al. "Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402)." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e21175-e21175. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21175.
Full textKim, Joori, Jeong-Oh Kim, Youn Soo Lee, Jung-Young Shin, Min Young Kim, Mi-Ran Lee, Seoree Kim, et al. "The changes of HER3 expression in head and neck cancer patients treated with induction chemotherapy." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e18004-e18004. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18004.
Full textMishra, Rosalin, Mary Kate Kilroy, Wasim Feroz, Hima Patel, Samar Alanazi, and Joan T. Garrett. "Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3916. http://dx.doi.org/10.1158/1538-7445.am2023-3916.
Full textÒdena, Andreu, Laia Monserrat, Fara Brasó-Maristany, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maurizio Scaltriti, et al. "Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–13–14—P5–13–14. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-13-14.
Full textManickavasagar, Thubeena, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo, et al. "HER3 expression and MEK activation in non-small-cell lung carcinoma." Lung Cancer Management 10, no. 2 (June 2021): LMT48. http://dx.doi.org/10.2217/lmt-2020-0031.
Full textRathore, Moeez Ghani, Wei Zhang, Michel'le Wright, Jordan Winter, Yamu Li, Zhenghe Wang, and Rui Wang. "Abstract 3177: Liver endothelium secreted LRG1 is a novel ligand of HER3 to promote metastatic colorectal cancer growth." Cancer Research 82, no. 12_Supplement (June 15, 2022): 3177. http://dx.doi.org/10.1158/1538-7445.am2022-3177.
Full textNishioka, Mariko, Chigusa Morizane, Mao Okada, Tomoyuki Satake, Nobuyoshi Hiraoka, Satoshi Nara, Tomoya Kakegawa, et al. "HER3 expression status following systemic chemotherapy treatment in biliary tract cancers." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e16153-e16153. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16153.
Full textXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young J. Gi, Thanasis Poullikkas, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, and Naoto T. Ueno. "Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis." Cancer Research 83, no. 8_Supplement (April 14, 2023): LB042. http://dx.doi.org/10.1158/1538-7445.am2023-lb042.
Full textKilroy, Mary Kate, SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Samar Alanazi, and Joan T. Garrett. "HER3 Alterations in Cancer and Potential Clinical Implications." Cancers 14, no. 24 (December 14, 2022): 6174. http://dx.doi.org/10.3390/cancers14246174.
Full textMishra, Rosalin, Mary Kate Kilroy, Hima Patel, Samar Alanazi, and Joan T. Garrett. "Abstract 5412: Role of her3 mutations on breast cancer oncogenesis." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5412. http://dx.doi.org/10.1158/1538-7445.am2022-5412.
Full textHwang, Hae Min, So Hyeon Kim, Sujin Ham, Minyoung Lee, Youlim Noh, Yu-Jin Kim, Changyun Lee, et al. "Abstract C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines." Molecular Cancer Therapeutics 22, no. 12_Supplement (December 1, 2023): C120. http://dx.doi.org/10.1158/1535-7163.targ-23-c120.
Full textHong, Woojae, Jeon Hwang-Bo, Hyelin Jeon, Minsung Ko, Joongyeon Choi, Yong-Joon Jeong, Jae-Hyun Park, et al. "A Comparative Study of the Hepatoprotective Effect of Centella asiatica Extract (CA-HE50) on Lipopolysaccharide/d-galactosamine-Induced Acute Liver Injury in C57BL/6 Mice." Nutrients 13, no. 11 (November 15, 2021): 4090. http://dx.doi.org/10.3390/nu13114090.
Full textTanner, Berno, Dirk Hasenclever, Katja Stern, Wiebke Schormann, Martin Bezler, Matthias Hermes, Marc Brulport, et al. "ErbB-3 Predicts Survival in Ovarian Cancer." Journal of Clinical Oncology 24, no. 26 (September 10, 2006): 4317–23. http://dx.doi.org/10.1200/jco.2005.04.8397.
Full textLi, Zhuolin, Chengzhang Shang, Gao An, Chaoshe Guo, W. Frank An, and Yi Yang. "Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2619. http://dx.doi.org/10.1158/1538-7445.am2024-2619.
Full textCruz, Rodrigo G. B., Stephen F. Madden, Cathy E. Richards, Sri HariKrishna Vellanki, Hanne Jahns, Lance Hudson, Joanna Fay, et al. "Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1." Cancers 13, no. 4 (February 19, 2021): 871. http://dx.doi.org/10.3390/cancers13040871.
Full textSatake, Tomoyuki, Chigusa Morizane, Mao Okada, Mariko Nishioka, Nobuyoshi Hiraoka, Satoshi Nara, Tomoya Kakegawa, et al. "Abstract 3405: Changes in HER3 expression associated with chemotherapy for pancreatic cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3405. http://dx.doi.org/10.1158/1538-7445.am2023-3405.
Full textLim, Malcolm, Tam H. Nguyen, Colleen Niland, Lynne E. Reid, Parmjit S. Jat, Jodi M. Saunus, and Sunil R. Lakhani. "Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases." Cancers 14, no. 3 (January 21, 2022): 533. http://dx.doi.org/10.3390/cancers14030533.
Full textKurmasheva, Raushan, Peter Houghton, Vanessa Del Pozo, Samson Ghilu, Ryuichi Nakamura, Pang-Dian Fan, Emily Jocoy, et al. "Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program." Cancer Research 84, no. 6_Supplement (March 22, 2024): 1088. http://dx.doi.org/10.1158/1538-7445.am2024-1088.
Full textBawa, I. Gusti Agung Gede, Sri Rahayu Santi, Wiwik Susanah Rita, Olan Suryanadi, and Gek Indyan. "Active compounds of Michelia champaca bark extract against Curvularia verruculosa fungi causing leaf spot disease in rice (Oryza sativa L.)." Journal of Applied and Natural Science 16, no. 1 (March 20, 2024): 420–26. http://dx.doi.org/10.31018/jans.v16i1.5406.
Full textRomaniello, Donatella, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, et al. "Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor." Cancers 12, no. 9 (August 24, 2020): 2394. http://dx.doi.org/10.3390/cancers12092394.
Full textJacobs, Bart, Loredana Vecchione, Nicholas Hoe, Jef De Schutter, Bart Biesmans, Sharat Singh, and Sabine Tejpar. "Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 3626. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3626.
Full textPark, Yeon Hee, Hyun Ae Jung, Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Oh-Nam Ok, Jeong Ju Seo, et al. "Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 637. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.637.
Full textKilroy, Mary K., Rosalin Mishra, Anastasia Stupecki, Wasim Feroz, Samar Alanazi, and Joan T. Garrett. "Abstract 3988: The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3988. http://dx.doi.org/10.1158/1538-7445.am2023-3988.
Full textRathore, Moeez Ghani, Kimberly Curry, Christina Boutros, Zhenghe Wang, Jordan Winter, and Rui Wang. "Abstract 3082: The liver microenvironment promotes glycolysis in metastatic colorectal cancer by activating her3." Cancer Research 84, no. 6_Supplement (March 22, 2024): 3082. http://dx.doi.org/10.1158/1538-7445.am2024-3082.
Full textRaghav, Kanwal Pratap Singh, Takayuki Yoshino, Hiroya Taniguchi, Sabine Tejpar, Arndt Vogel, Zev A. Wainberg, Kensei Yamaguchi, et al. "An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)." Journal of Clinical Oncology 39, no. 3_suppl (January 20, 2021): TPS157. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.tps157.
Full textKilroy, Mary K., Briley Park, Rosalin Mishra, Wasim Feroz, Cecilia Wischmeier, and Joan T. Garrett. "Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis." Cancer Research 84, no. 6_Supplement (March 22, 2024): 7150. http://dx.doi.org/10.1158/1538-7445.am2024-7150.
Full textWang, Lina, Meijun Xiong, Xinju Gao, Chengang Zhou, Yu Han, Yanchun Li, Junhao Wang, Lili Shi, Gang Qin, and Paul H. Song. "Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2114. http://dx.doi.org/10.1158/1538-7445.am2024-2114.
Full textBartsch, Rupert, Anna Sophie Berghoff, Zsuzsanna Bago-Horvath, Matthias Preusser, Guenther G. Steger, Margareta Rudas, Peter Birner, and Christoph Zielinski. "Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 611. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.611.
Full textAl-Akhrass, Hussein, James R. W. Conway, Annemarie Svane Aavild Poulsen, Ilkka Paatero, Jasmin Kaivola, Artur Padzik, Olav M. Andersen, and Johanna Ivaska. "A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance." Oncogene 40, no. 7 (January 8, 2021): 1300–1317. http://dx.doi.org/10.1038/s41388-020-01604-5.
Full textAlanazi, Samar M., Rosalin Mishra, Hima Patel, Mary K. Kilroy, and Joan T. Garrett. "Abstract 5661: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5661. http://dx.doi.org/10.1158/1538-7445.am2022-5661.
Full textBoutros, Christina S., Alexander W. Loftus, Moeez Rathore, Mehrdad Zarei, Kimberly Curry, Jordan M. Winter, and Rui Wang. "Abstract 445: Determining the molecular and biologic effects of HER3 and IDH1 antagonism on liver endothelium-PDAC crosstalk." Cancer Research 84, no. 6_Supplement (March 22, 2024): 445. http://dx.doi.org/10.1158/1538-7445.am2024-445.
Full textKojima, Yuki, Kazuki Sudo, Hiroshi Yoshida, Shu Yazaki, Momoko Tokura, Shosuke Kita, Kasumi Yamamoto, et al. "Abstract 5083: Changes in HER3 expression profiles between initial diagnosis and recurrence in gynecologic cancers." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5083. http://dx.doi.org/10.1158/1538-7445.am2022-5083.
Full text